Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
A paper in the Journal of the National Cancer Institute finds that almost 20% of patients in middle-stage cancer drug trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback